FANCE 293T Cell Transient Overexpression Lysate(Denatured)
- Known as:
- FANCE 293T Cell Transient Overexpression Lysate(Denatured)
- Catalog number:
- H00002178-T01
- Product Quantity:
- 100 uL
- Category:
- -
- Supplier:
- Abno
- Gene target:
- FANCE 293T Cell Transient Overexpression Lysate(Denatured)
Related genes to: FANCE 293T Cell Transient Overexpression Lysate(Denatured)
- Gene:
- FANCE NIH gene
- Name:
- FA complementation group E
- Previous symbol:
- FACE
- Synonyms:
- FAE
- Chromosome:
- 6p21.31
- Locus Type:
- gene with protein product
- Date approved:
- 1996-04-09
- Date modifiied:
- 2019-04-23
Related products to: FANCE 293T Cell Transient Overexpression Lysate(Denatured)
Related articles to: FANCE 293T Cell Transient Overexpression Lysate(Denatured)
- The 6th edition of the WHO Classification of Digestive System Tumours distinguishes amphicrine-like carcinomas (ALCs) from mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs). Acinar cell carcinomas (ACCs) with an intimately admixed and not separated neuroendocrine component comprising >30% of the tumour are classified as amphicrine-like ACCs (AL-ACCs). We characterised the genomic landscape of pancreatic ACCs and AL-ACCs to validate current classification and identify therapeutic targets. - Source: PubMed
Publication date: 2026/09/04
Kim ChankyungYun Hyun-NamKim DeokhoonJeong Byung-KwanShin JinhoYoo ChanghoonOh DongwookKim Kyu-PyoSong Tae JunSong Ki ByungLee Seung SooKim Song CheolHong Seung-Mo - Ovarian cancer is one of the leading causes of death from gynecological cancer worldwide. Genetic mutations in genes involved in key cellular functions such as BRCA1/2 play a central role in tumorigenesis and have major implications for targeted therapeutic strategies, especially the use of poly (ADP-ribose) polymerase (PARP) inhibitors. - Source: PubMed
Ammous-Boukhris NihelAbdelmaksoud-Dammak RaniaFeki AmeniKhemiri SouhirCharfi SlimSallemi-Boudawara TahiaDaoud JamelKhanfir AfefGargouri Raja Mokdad - To investigate the predictive value of the cancer antigen-125 elimination rate constant K (KELIM) for treatment response and prognosis in patients with advanced high-grade serous ovarian cancer (HGSOC) undergoing neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS), and to analyze the combined prognostic significance of KELIM and the mutation status of breast cancer susceptibility gene (). - Source: PubMed
Li YueboLi MengruZhang XiuyunXu HanjieLi JieLiu HanyuanPeng Cheng - Androgen deprivation therapy (ADT) is widely employed in the management of advanced prostate cancer, with luteinizing hormone-releasing hormone (LHRH) agonists such as leuprolide and goserelin being common options. However, pharmacological and metabolic differences between these agents may affect the efficacy of hormonal suppression and adverse event profiles. This study compared the effects of leuprolide (22.5 and 45 mg) and goserelin (10.8 mg) on prostate-specific antigen (PSA) and testosterone reduction, as well as their metabolic and cardiovascular impacts and the influence of genetic variants on therapeutic response. - Source: PubMed
Publication date: 2026/08/21
Freitas Carla Simone MoreiraRocha-Silva FabianaMarques-Silva Thaís Almeidade Oliveira Ana Carolina Ribeiroda Silva Sérgio GomesSantos Cardoso Fabrizio DosSoares Aleida Nazareth - Hereditary breast cancer accounts for approximately 5 to 10% of all breast cancer cases. Mutations in the gene, which plays a central role in DNA repair and cell cycle regulation, are the main cause of these familial forms and are strongly associated with aggressive subtypes, particularly triple-negative breast cancer. - Source: PubMed
Publication date: 2026/01/19
Tounkara Fatoumata KorikaTéguété IbrahimaSidibé Fatoumata MatokomaDiallo Dapa Aly